May 26, 2026 Sweden
UBI: Life Science in Focus as GMP Approval Boosts Umeå’s Strategic Position
Umeå Biotech Incubator highlights Diamyd Medical’s GMP approval for its Umeå facility, noting its strategic importance for life science, regional preparedness and future pharmaceutical manufacturing. In the interview, Sofia Mayans, Head of Manufacturing Site Umeå, describes the approval as a major strength for the region.
Read the full article here
Information presented here are not press releases and may include excerpts from and links to externally published content. Diamyd Medical is not responsible for externally published content.